Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2Phase NA 1Phase 4 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 61Prostatic Neoplasms 43Lung Neoplasms 35Multiple Myeloma 34Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 22Colorectal Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Neoplasm Metastasis 19Ovarian Neoplasms 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Leukemia, Myeloid, Acute 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Nasopharyngeal Carcinoma 11Myasthenia Gravis 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Melanoma 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7

Interventions

Sunitinib 2Midazolam 1Imatinib Mesylate 1IDRX-42 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × 30 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT07585266 2026-05-13

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

GlaxoSmithKline

Phase 3 Not yet recruiting
800 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡